Helicobacter pylori and nonmalignant disease

Area of Science:

• Gastroenterology
• Microbiology

Background:

• Helicobacter pylori (H. pylori) eradication is the standard treatment for peptic ulcer disease.
• The efficacy of H. pylori eradication for other associated conditions is under ongoing clinical investigation.

Purpose of the Study:

• To summarize the current evidence for H. pylori eradication in various clinical conditions beyond peptic ulcer disease.
• To provide insights into the management of dyspepsia and related gastrointestinal disorders.

Main Methods:

• Review of current evidence and clinical trial data.
• Analysis of H. pylori eradication's impact on NSAID-associated ulcers, nonulcer dyspepsia, and GERD.
• Evaluation of cost-effectiveness of H. pylori 'test and treat' strategy.

Main Results:

• H. pylori eradication is advisable for preventing NSAID-induced ulcers but shows no advantage for healing active ulcers during PPI treatment.
• Eradication protects against aspirin-induced bleeding but is insufficient for secondary prevention of NSAID ulcer complications.
• A small benefit favors H. pylori eradication for nonulcer dyspepsia; it does not influence the clinical course of reflux esophagitis.
• The H. pylori 'test and treat' strategy is more cost-effective than endoscopy for dyspepsia management in primary care.

Conclusions:

• H. pylori eradication plays a nuanced role in managing NSAID-associated gastrointestinal issues.
• Evidence supports H. pylori eradication for nonulcer dyspepsia and specific NSAID-related bleeding prevention.
• H. pylori eradication does not impact GERD, and 'test and treat' is cost-effective for dyspepsia.